)
Spruce Biosciences (SPRB) investor relations material
Spruce Biosciences 3rd Annual Guggenheim Healthcare Innovation Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Lead asset and regulatory pathway
Tralesinidase alfa is a CSF-delivered enzyme replacement therapy fused to truncated IGF-2 for neuronal and lysosomal penetration; delivery is weekly or every other week via port and Ommaya reservoir, with profound heparan sulfate effects and supportive safety and efficacy data.
BLA submission is planned for December under the accelerated-approval pathway, using heparan sulfate non-reducing ends as the primary endpoint; FDA said the biomarker is reasonably likely to predict clinical benefit, while acceptance remains a review issue.
FDA pre-BLA meetings covered CMC and clinical content; no AdCom requirement has been discussed or signaled by FDA.
Manufacturing and clinical evidence
First drug-substance and drug-product PPQ batches are planned for the BLA; the second PPQ will be submitted during review, with analytical reports targeted before the mid-cycle meeting; drug-product manufacturing transferred from Vetter to Samsung Biologics for qualification.
Confirmatory trial is initiated and must be underway at BLA submission, but need not be fully recruited by launch; expanded access is intended to provide product access before commercial availability.
Confirmatory-trial primary endpoint is Bayley cognitive raw score; analyses include sensitivity methods and propensity matching on age and baseline cognition to address imbalances against natural-history patients.
NfL, GM2, GM3 and other biomarker findings are planned for presentation at the WORLD meeting in February in San Diego.
Market and launch plans
Preliminary U.S. claims analysis identified ~1,400 MPS III patients, with an estimated ~450 diagnosed MPS IIIB; incidence-based estimates span 250 to ~2,000 patients.
Five U.S. centers of excellence specialize in MPS; a concentrated sales team is expected to reach the patient pool through these centers.
Planned cadence is BLA submission in December, acceptance in February and potential approval around August; Rare Pediatric Disease designation would qualify for a PRV, with proceeds planned to fund U.S. commercialization.
European approval remains a goal; the initiative is being revamped starting in Q4, with local distributors, partners or named-patient programs under consideration.
- TA-ERT’s December BLA advances amid a funding gap and CRHX-101’s separation into Adrenyx.SPRB
Q3 2026 - Lead therapy for MPS IIIB shows strong efficacy, with BLA submission and global launch planned.SPRB
H.C. Wainwright 28th Annual Global Investment Conference - Q2 2026 net loss was $16.2M as R&D spending surged, with $96.3M in cash and new leadership.SPRB
Q2 2026 - Lead therapy for MPS IIIB nears approval, showing strong efficacy and commercial readiness.SPRB
Jefferies Global Healthcare Conference 2026 - Directors elected, all proposals approved, and strategic plans funded for regulatory milestones.SPRB
AGM 2026 - TA-ERT advances toward BLA submission as finances and leadership strengthen.SPRB
Q1 2026 - Annual meeting to elect directors, ratify auditor, and vote on executive pay and its frequency.SPRB
Proxy filing - Proxy covers director elections, auditor ratification, executive pay, and governance after a 1:75 reverse split.SPRB
Proxy filing - Lead therapy for MPS IIIB advances toward Q4 BLA submission with strong clinical and regulatory momentum.SPRB
The Citizens Life Sciences Conference 2026
)
)
)
)
)
)
)
)